Cooperative Agreement 72061120CA00005

This $1,303,086 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 Allergy and Infectious Diseases Research supports a longitudinal cohort study on the impact of early childhood malaria prevention interventions on malaria burden among school-age children in Ghana. The study, titled "IMPACT OF EARLY CHILDHOOD MALARIA PREVENTION ON MALARIA RISK AT SCHOOL ENTRY (ERASE)", will assess the epidemiological and immunological outcomes of...

This Project Grant award of $160,000 from the Department of State Bureau of African Affairs supports efforts by Adpp Angola under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) Programs (CFDA 19.029) to prevent mother-to-child transmission of HIV in Angola. Key deliverables include strengthening HIV care and treatment at health facilities, increasing community engagement, and building clinical laboratory and supply chain infrastructure from August 6, 2021 to September 30, 2021....

This Project Grant award of $335,559.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will fund a pilot feasibility study to assess the impact of a Focal Mass Drug Administration (FMDA) program for reducing malaria in pregnancy (MIP) in rural Western Uganda. The study aims to determine the feasibility, acceptability, and preliminary effectiveness of providing FMDA with dihydroartemisinin-piperaquine...

This $446,025 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to study the impact of spatial repellents on asymptomatic Plasmodium falciparum malaria infections and transmission in Western Kenya. The key objectives are to: 1) quantify reductions in asymptomatic malaria prevalence after introducing spatial repellents by screening 9,000 blood samples, and 2) compare...

This Project Grant award from the Fogarty International Center (CFDA 93.989 - International Research and Research Training) provides $108,916 to the Kamuzu University of Health Sciences in Malawi to characterize the pharmacokinetic and safety profiles of the antimalarial drugs artemether-lumefantrine and amodiaquine in two key target populations: children with severe acute malnutrition and adults living with HIV on dolutegravir-based antiretroviral therapy. The goal is to inform optimal dosing...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research to evaluate a genomic surveillance approach for identifying mutations associated with artemisinin resistance in Plasmodium falciparum malaria parasites in Africa. The $1,553,810 award to the University of Maryland, Baltimore will fund a multi-year research project with the following key objectives:...

The Department of State Bureau of African Affairs awarded a $110,000 project grant to Treatment Advocacy And Litera CY Campaign to implement the COMMUNITY LED MONITORING TO IMPROVE QUALITY OF HIV CARE IN ZAMBIA THROUGH CLIENT FEEDBACK project from March 1, 2022 to December 30, 2022. Under this award, Treatment Advocacy And Litera CY Campaign will work to improve HIV care quality in Zambia by establishing a community-led monitoring program that gathers client feedback. The grant is part of the...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $777,072 to The University of Kentucky Research Foundation to conduct research on developing new antimalarial drug combinations based on ATP4 inhibitors, such as SJ733, that can prevent the development of drug resistance. The key goals are to understand the factors driving the efficacy and resistance acquisition risk of potential clinical...

This $15,221,142 Cooperative Agreement award from the Centers for Disease Control and Prevention (CDC) under the Global AIDS Federal Grant Program (CFDA 93.067) aims to develop, implement, and sustain high-quality comprehensive facility and community-based HIV 95-95-95 cascade activities for children, adolescents, and adults in Cameroon under the President's Emergency Plan for AIDS Relief (PEPFAR). The overarching goal is to implement HIV prevention, care, and treatment services and reduce...

This federal Cooperative Agreement award, funded by the U.S. Agency for International Development (USAID) under the USAID Foreign Assistance for Programs Overseas (CFDA 98.001) program, supports the delivery of quality, high-impact malaria control and prevention services in The Gambia. The $2,580,000 award to Jhpiego Corp, a non-profit global health organization affiliated with Johns Hopkins University, will contribute to a measurable reduction in malaria mortality and morbidity in alignment...